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METABOLISM 
Can metabolomic profiling predict response to therapy? 
Catherine M. McGrath and Stephen P. Young 
Standfirst 
Shifts in cellular metabolism are central to activation, differentiation and proliferation of 
inflammatory cells and can contribute to the pathogenesis of inflammatory diseases. Integrating 
metabolomics data with other omics data is a major challenge but might enable clinicians to stratify 
stages of disease and response to therapy in patients with rheumatoid arthritis. 
 
Refers to: Teitsma, X.M. et al. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-
target tocilizumab, methotrexate, or the combination: insights from systems biology. Arthritis Res. Ther. 20, 230 (2018)  
 
 
Main text 
Rheumatoid arthritis (RA) is prevalent in ~1 % of the population and is responsible for substantial 
financial and social burden. RA is a systemic disease, but the most obvious manifestations are in the 
joints. Current therapeutic best practice is to identify the disease at an early stage and treat it 
aggressively with a step-up regimen aimed at achieving complete clinical remission. This strategy 
typically commences with methotrexate and, if needed, is followed up with addition of conventional 
synthetic or biologic therapeutic agents that target pro-inflammatory cytokines. Unfortunately, 
although the goal of remission is becoming more attainable, success is not universally achieved (1). 
The search is on, therefore, not only to establish treatment regimens that can induce sustained 
clinical remission in patients with RA, but also to develop technologies to predict which therapeutic 
options will work in individual patients. A promising new study from Teitsma et al. (2) combines 
omics technologies to show that metabolite profiling of serum, when combined with transcriptomics 
and protein analysis, is able to stratify patient responses to methotrexate, tocilizumab or a 
combination of these drugs.  
Cellular metabolism is required to sustain cells and tissues, but metabolic programs operating (at the 
level of genes, gene transcripts, proteins and metabolites) can vary according to cell type, are 
altered when cells activate, proliferate or differentiate and are perturbed by disease (3). By being at 
downstream at the convergence of multiple pathways, small molecule metabolite profiling (known 
as metabolomics) of biofluids can provide signatures that might be able to discriminate between 
disease and health. Different tissues and immune cells might respond metabolically in unique ways 
to inflammatory mediators such as cytokines, and thereby biofluid metabolite profiles reflect these 
metabolic processes and provide predictors of responses to therapy that are targeted at these 
mediators.  
Teitsma et al (2) used clinical data which was originally derived from the 2-year multicentre phase III 
double-blind placebo-controlled U-Act-Early strategy trial (ClinicalTrials.gov identifier NCT01034137), 
which took 317 DMARD-naive patients with newly diagnosed RA, and randomized them to start 
treatment with tocilizumab (a humanized anti-IL-6 receptor monoclonal antibody), step-up 
methotrexate or a combination of the two drugs. Patients were treated-to-target until sustained 
remission was achieved, defined as DAS28 <2.6 with ≤4 swollen joints for ≥24 weeks (4). In this sub-
group of 60 patients (2), baseline serum metabolic profiles obtained on mass spectrometry 
platforms were used to validate ‘oxidative stress’, ‘amines’ and ‘oxylipins’ in 37 patients with RA 
(median duration of symptoms 23 days, inter-quartile range 18-40), and achieving sustained drug 
free remission (sDFR) was compared to serum profiles from 23 patients from the study who did not, 
as a control. 
Distinct baseline metabolic pathways identified in sera from patients achieving sDFR were 
highlighted across the three treatment arms including ‘histidine metabolism’ in the tocilizumab and 
methotrexate arm, ‘arachidonic acid metabolism’ in the tocilizumab arm and ‘arginine and proline 
metabolism’ in the methotrexate-only arm (2). Although only the top pathway in each of the 
treatment arms was highlighted, we note that the ‘histidine metabolism’ pathway in the 
methotrexate arm also showed similar levels of significance (p=0.025, versus p=0.022 for ‘arginine 
and proline’). Interestingly, Kanarek et al. (5) previously emphasised the importance of histidine 
metabolism in the sensitivity to methotrexate in cancer, and the new data from Teitsma et al. (2) 
provide further links between histidine metabolism and methotrexate efficacy.  
Previous publications from the U-Act-Early study have already included other packets of omics data 
(6)(7). High-throughput whole transcriptomic ribonucleic acid sequencing (RNA-seq) from CD4+ T 
helper cells and CD14+ monocytes isolated at baseline from whole blood samples was used to 
identify differential gene expression networks from these same 60 patients (6). That study showed 
different clusters of expressed genes were significant for CD4+ T cells, depending on the subsequent 
treatment arm, with three pathways identified (6). For example, in the tocilizumab and 
methotrexate arm, pathways related to transcription and translation were important, whereas 
pathways related to migration of white blood cells and G-protein coupled receptors were significant 
in the tocilizumab arm. In the methotrexate arm, pathways relating to response to a bacterial or 
biotic stimulus were highlighted. No relevant networks could be identified in the sequenced CD14+ 
monocytes. This study (6) indicated that at least in CD4+ T helper cells, differential expression of 
blood cell genes can be linked to drug efficacy but with the limitation being the focus on blood cells 
without any analysis of synovium (the main site of inflammation in RA). In another publication, 
proteomics data (obtained at baseline from serum) from the same 60 patients showed multiple 
proteins associated with achieving sDFR, but the addition of seven candidate protein biomarkers 
identified to clinical predictors did not enhance the prognosis of methotrexate treatment response 
(7), suggesting that proteomics data alone are not sufficiently discriminatory and that further 
integration of data is required. Similarly, while IL-6 signalling (the target of tocilizumab) has an 
important role in metabolism, the baseline level of IL-6 in blood seems to be a weak predictor of the 
response to tocilizumab in RA, emphasising that individual blood parameters can be less informative 
in isolation (8). 
Previous work has suggested that baseline urine metabolic profiles can predict responses to 
biological therapies using TNF inhibitors (9). Metabolites linked to degradation of amino acids were 
identified as predictors of drug response. TNF is known to drive rheumatoid cachexia, in which 
muscle loss is substantial and so would drive protein degradation leading to the appearance of 
amino acid by-products in the urine. The presence of these by-products would indicate the 
importance of TNF in driving disease in those patients and thus their responses to TNF-targeted 
therapy. Metabolic profiles in blood in very early arthritis are heterogeneous (10), and may reflect 
whether the patient will develop chronic arthritis or not, in addition to being useful in predicting 
responses to therapy (2). 
Metabolomics undoubtedly has more to offer in future studies of chronic disease, and especially 
when integrated with other omics technologies, metabolic profiling of blood or urine might enable 
integration of signals from all the tissues and cells that contribute to early stages of disease. 
Integration of the different omics technologies by Teitsma et al (2) in their study of early RA is an 
elegant example, and suggests a pathway to fully personalized therapy.  
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